TY - JOUR
T1 - Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline)
T2 - A Prospective Observational Study of Patients With Polycythemia Vera in the United States
AU - Mesa, Ruben
AU - Boccia, Ralph V.
AU - Grunwald, Michael R.
AU - Oh, Stephen T.
AU - Colucci, Philomena
AU - Paranagama, Dilan
AU - Parasuraman, Shreekant
AU - Stein, Brady L.
N1 - Funding Information:
Writing assistance was provided by Tania Iqbal, PhD, at Complete Healthcare Communications, LLC (West Chester, PA), a CHC Group company, and funded by Incyte Corporation.
Funding Information:
R.M. served as a consultant for Novartis and received research funding from CTI Biopharma, Genentech, Gilead, Incyte Corporation, NS Pharma, Pfizer, and Promedior. R.V.B. received honoraria from Incyte Corporation. M.R.G. has received honoraria from Alexion, Amgen, ARIAD, Cardinal Health, Celgene, Incyte Corporation, and Pfizer; served as a consultant for Incyte Corporation; received research funding from Amgen, Forma Therapeutics, Genentech, Incyte Corporation, and Janssen; and is a stockholder of Medtronic. S.T.O. served as a consultant for CTI Biopharma, Incyte Corporation, and Pfizer; and received research funding from CTI Biopharma, Gilead, Incyte Corporation, and Janssen. P.C., D.P., and S.P. are employees and stockholders of Incyte Corporation. B.L.S. served as a consultant and member of the advisory committees for Incyte Corporation.
Publisher Copyright:
© 2018 The Authors
PY - 2018/9
Y1 - 2018/9
N2 - Data from REVEAL (Prospective Observational Study of Patients With Polycythemia Vera in US Clinical Practices; n = 2309), the first study of its kind, confirm that many patients experience quality of life and work productivity impairments that might negatively affect their lives. In the future, longitudinal data from REVEAL will be important for evaluating how such burdens change over time. Background: Patients with polycythemia vera (PV) often experience symptoms that adversely affect their quality of life (QoL). The ongoing, prospective, observational REVEAL (Prospective Observational Study of Patients With Polycythemia Vera in US Clinical Practices) study was designed to collect contemporary data regarding burden of disease, clinical management, patient-reported outcomes (PROs), and health care resource utilization from adult patients with PV in the United States. Patients and Methods: Data on PROs were collected at enrollment using the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS; range, 0-100); the European Organization for Research and Treatment of Cancer–Core Quality of Life Questionnaire, version 3.0 (EORTC QLQ-C30; range, 0-100); and the Work Productivity and Activity Impairment Questionnaire–Specific Health Problem (WPAI-SHP; range, 0%-100%). Results: Among 2309 patients, mean (SD) disease duration was 5.8 (6.1) years and Charlson Comorbidity Index was 3.4 (0.8); 54.0% (1247/2309) were male. Mean (SD) MPN-SAF TSS was 18.8 (15.5). The most common symptoms were fatigue (80.1% [1844/2302]), early satiety (60.9% [1402/2302]), and inactivity (57.6% [1324/2302]). The most common severe symptoms were fatigue (16.8% [387/2302]), itching (13.4% [308/2302]), and inactivity (11.8% [271/2302]). The mean (SD) EORTC QLQ-C30 global health status/QoL score was 73.1 (23.2): mean functional subscale scores ranged from 80.5 (23.9) for cognitive functioning to 85.7 (24.6) for social functioning. The mean WPAI-SHP activity impairment score was 19.7% (n = 2300). Employed patients had mean WPAI-SHP scores for absenteeism, presenteeism, and overall work impairment of 3.2% (n = 810), 12.1% (n = 807), and 13.4% (n = 802), respectively. Conclusion: These data confirm that many patients with PV experience symptoms, QoL impairments, and work productivity impairments that negatively affect their lives. Longitudinal data from REVEAL will be important for evaluating how PROs change over time in these patients.
AB - Data from REVEAL (Prospective Observational Study of Patients With Polycythemia Vera in US Clinical Practices; n = 2309), the first study of its kind, confirm that many patients experience quality of life and work productivity impairments that might negatively affect their lives. In the future, longitudinal data from REVEAL will be important for evaluating how such burdens change over time. Background: Patients with polycythemia vera (PV) often experience symptoms that adversely affect their quality of life (QoL). The ongoing, prospective, observational REVEAL (Prospective Observational Study of Patients With Polycythemia Vera in US Clinical Practices) study was designed to collect contemporary data regarding burden of disease, clinical management, patient-reported outcomes (PROs), and health care resource utilization from adult patients with PV in the United States. Patients and Methods: Data on PROs were collected at enrollment using the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS; range, 0-100); the European Organization for Research and Treatment of Cancer–Core Quality of Life Questionnaire, version 3.0 (EORTC QLQ-C30; range, 0-100); and the Work Productivity and Activity Impairment Questionnaire–Specific Health Problem (WPAI-SHP; range, 0%-100%). Results: Among 2309 patients, mean (SD) disease duration was 5.8 (6.1) years and Charlson Comorbidity Index was 3.4 (0.8); 54.0% (1247/2309) were male. Mean (SD) MPN-SAF TSS was 18.8 (15.5). The most common symptoms were fatigue (80.1% [1844/2302]), early satiety (60.9% [1402/2302]), and inactivity (57.6% [1324/2302]). The most common severe symptoms were fatigue (16.8% [387/2302]), itching (13.4% [308/2302]), and inactivity (11.8% [271/2302]). The mean (SD) EORTC QLQ-C30 global health status/QoL score was 73.1 (23.2): mean functional subscale scores ranged from 80.5 (23.9) for cognitive functioning to 85.7 (24.6) for social functioning. The mean WPAI-SHP activity impairment score was 19.7% (n = 2300). Employed patients had mean WPAI-SHP scores for absenteeism, presenteeism, and overall work impairment of 3.2% (n = 810), 12.1% (n = 807), and 13.4% (n = 802), respectively. Conclusion: These data confirm that many patients with PV experience symptoms, QoL impairments, and work productivity impairments that negatively affect their lives. Longitudinal data from REVEAL will be important for evaluating how PROs change over time in these patients.
KW - Activity impairment
KW - Myeloproliferative neoplasm
KW - Quality of life
KW - Symptoms
KW - Work productivity
UR - http://www.scopus.com/inward/record.url?scp=85049326326&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85049326326&partnerID=8YFLogxK
U2 - 10.1016/j.clml.2018.05.020
DO - 10.1016/j.clml.2018.05.020
M3 - Article
AN - SCOPUS:85049326326
VL - 18
SP - 590
EP - 596
JO - Clinical Lymphoma
JF - Clinical Lymphoma
SN - 2152-2669
IS - 9
ER -